Literature DB >> 20417147

High avidity cytokine autoantibodies in health and disease: pathogenesis and mechanisms.

Masato Watanabe1, Kanji Uchida, Kazuhide Nakagaki, Bruce C Trapnell, Koh Nakata.   

Abstract

Numerous reports have documented the presence of autoantibodies working against naturally occurring cytokines in humans in health and disease. In most instances, their physiological and pathophysiological significance remains unknown. However, recent advances in the methodologies for detecting cytokine autoantibodies and their application in research focused on specific disorders have shown that some cytokine autoantibodies play an important role in the pathogenesis of disease. Additionally, levels of cytokine autoantibodies may also correlate with disease severity and progression in certain infectious and autoimmune diseases but not in others. This suggests that cytokine-specific pathogenic differences exist. While multiple lines of evidence support the notion that high avidity cytokine autoantibodies are present and likely to be ubiquitous in healthy individuals, their potential physiological role, if any, is less clear. It is believed that they may function by scavenging pro-inflammatory cytokines and thereby inhibiting deleterious 'endocrine' effects, or by serving as carrier proteins, providing a 'reservoir' of inactive cytokines and thus modulating cytokine bioactivity. A central hypothesis is that sustained or repeated high-level exposure to cytokines triggers defects in T-cell tolerance, resulting in the expansion of existing cytokine autoantibody-producing B cells.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20417147     DOI: 10.1016/j.cytogfr.2010.03.003

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  19 in total

1.  IL-2 antibodies in type 1 diabetes and during IL-2 therapy.

Authors:  Guillaume Churlaud; Michelle Rosenzwajg; Patrice Cacoub; David Saadoun; Dominique Valteau-Couanet; Nathalie Chaput; Alberto Pugliese; David Klatzmann
Journal:  Diabetologia       Date:  2018-06-02       Impact factor: 10.122

Review 2.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 3.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

4.  Familial Association of Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies in Inflammatory Bowel Disease.

Authors:  Sandra S Wright; Anna Trauernicht; Erin Bonkowski; Courtney A McCall; Elizabeth A Maier; Ramona Bezold; Kathleen Lake; Claudia Chalk; Bruce C Trapnell; Mi-Ok Kim; Subra Kugathasan; Lee A Denson
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-05       Impact factor: 2.839

5.  Use of the VH6-1 gene segment to code for anti-interleukin-18 autoantibodies in multiple sclerosis.

Authors:  Marina Tiumentseva; Vera Morozova; Aleksandr Zakabunin; Denis Korobko; Nadezhda Malkova; Maksim Filipenko; Nina Tikunova
Journal:  Immunogenetics       Date:  2016-01-07       Impact factor: 2.846

6.  Paediatric Crohn disease patients with stricturing behaviour exhibit ileal granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibody production and reduced neutrophil bacterial killing and GM-CSF bioactivity.

Authors:  I Jurickova; M H Collins; C Chalk; A Seese; R Bezold; K Lake; D von Allmen; J S Frischer; R A Falcone; B C Trapnell; L A Denson
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

7.  Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics.

Authors:  Li Xue; Bonita Rup
Journal:  AAPS J       Date:  2013-06-13       Impact factor: 4.009

8.  Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis.

Authors:  Lindsey B Rosen; Alexandra F Freeman; Lauren M Yang; Kamonwan Jutivorakool; Kenneth N Olivier; Nasikarn Angkasekwinai; Yupin Suputtamongkol; John E Bennett; Vasilios Pyrgos; Peter R Williamson; Li Ding; Steven M Holland; Sarah K Browne
Journal:  J Immunol       Date:  2013-03-18       Impact factor: 5.422

9.  Plasma Anti-Glial Fibrillary Acidic Protein Autoantibody Levels during the Acute and Chronic Phases of Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot Study.

Authors:  Kevin K W Wang; Zhihui Yang; John K Yue; Zhiqun Zhang; Ethan A Winkler; Ava M Puccio; Ramon Diaz-Arrastia; Hester F Lingsma; Esther L Yuh; Pratik Mukherjee; Alex B Valadka; Wayne A Gordon; David O Okonkwo; Geoffrey T Manley; Shelly R Cooper; Kristen Dams-O'Connor; Allison J Hricik; Tomoo Inoue; Andrew I R Maas; David K Menon; David M Schnyer; Tuhin K Sinha; Mary J Vassar
Journal:  J Neurotrauma       Date:  2016-02-01       Impact factor: 5.269

10.  Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency.

Authors:  Jolan E Walter; Lindsey B Rosen; Krisztian Csomos; Jacob M Rosenberg; Divij Mathew; Marton Keszei; Boglarka Ujhazi; Karin Chen; Yu Nee Lee; Irit Tirosh; Kerry Dobbs; Waleed Al-Herz; Morton J Cowan; Jennifer Puck; Jack J Bleesing; Michael S Grimley; Harry Malech; Suk See De Ravin; Andrew R Gennery; Roshini S Abraham; Avni Y Joshi; Thomas G Boyce; Manish J Butte; Kari C Nadeau; Imelda Balboni; Kathleen E Sullivan; Javeed Akhter; Mehdi Adeli; Reem A El-Feky; Dalia H El-Ghoneimy; Ghassan Dbaibo; Rima Wakim; Chiara Azzari; Paolo Palma; Caterina Cancrini; Kelly Capuder; Antonio Condino-Neto; Beatriz T Costa-Carvalho; Joao Bosco Oliveira; Chaim Roifman; David Buchbinder; Attila Kumanovics; Jose Luis Franco; Tim Niehues; Catharina Schuetz; Taco Kuijpers; Christina Yee; Janet Chou; Michel J Masaad; Raif Geha; Gulbu Uzel; Rebecca Gelman; Steven M Holland; Mike Recher; Paul J Utz; Sarah K Browne; Luigi D Notarangelo
Journal:  J Clin Invest       Date:  2015-10-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.